Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Takeda announced that the Food and Drug Administration (FDA) has approved Dexilant SoluTab (dexlansoprazole) delayed-release orally disintegrating tabs, a new formulation that melts in the patient’s mouth.
Dexilant SoluTab is a proton pump inhibitor (PPI) that is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) and the maintenance of healed erosive esophagitis (EE) and relief of heartburn in patients aged ≥18 years.
RELATED: GERD Risks Jumps in Women Post-IVF – But Why?
Dexilant SoluTab consists of dual delayed release (DDR) technology that provides 2 releases of medication. It suppresses gastric acid secretion by specific inhibition of the (H+ , K+ )-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.
Dexilant is already available as 30mg and 60mg strength delayed-release capsules in 30-, 90-, and 1000-count bottles. Dexilant SoluTab will be available as 30mg strength delayed-release orally disintegrating tablets in 100-count unit dose packs.
For more information call (877) 825-3327 or visit Takeda.us.
